The $800 million pill: The truth behind the cost of new drugs

Por Moore, John P.
Publicado em 2004

Entry inhibitors as topical microbicides to prevent HIV-1 sexual transmission

Por Moore, John P
Publicado em 2006

The invisible cure: Africa, the West, and the fight against AIDS

Por Moore, John P.
Publicado em 2007

Will Multiple Coreceptors Need To Be Targeted by Inhibitors of Human Immunodeficiency Virus Type 1 Entry?

Por Zhang, Yi-jun, Moore, John P.
Publicado em 1999

The entry of entry inhibitors: A fusion of science and medicine

Por Moore, John P., Doms, Robert W.
Publicado em 2003

HIV-1 Membrane Fusion: Targets of Opportunity

Por Doms, Robert W., Moore, John P.
Publicado em 2000

A pièce de resistance: how HIV-1 escapes small molecule CCR5 inhibitors

Por Moore, John P., Kuritzkes, Daniel R.
Publicado em 2009

Good CoP, bad CoP? Interrogating the immune responses to primate lentiviral vaccines

Por Klasse, Per Johan, Moore, John P
Publicado em 2012

Editorial: Current advances and challenges in understanding plant desiccation tolerance

Por Moore, John P., Farrant, Jill M.
Publicado no Front Plant Sci (2015)

A stamp on the envelope

Por SANDERS, ROGIER W., MOORE, JOHN P.
Publicado no Nature (2014)

Native‐like Env trimers as a platform for HIV‐1 vaccine design

Por Sanders, Rogier W., Moore, John P.
Publicado no Immunol Rev (2017)

A role for pectin-associated arabinans in maintaining the flexibility of the plant cell wall during water deficit stress

Por Moore, John P, Farrant, Jill M, Driouich, Azeddine
Publicado em 2008

Which Topical Microbicides for Blocking HIV-1 Transmission Will Work in the Real World?

Por Klasse, Per Johan, Shattock, Robin J, Moore, John P
Publicado em 2006

Association of Structural Changes in the V2 and V3 Loops of the gp120 Envelope Glycoprotein with Acquisition of Neutralization Resistance in a Simian-Human Immunodeficiency Virus P...

Por Ye, Yongjun, Si, Zhi Hai, Moore, John P., Sodroski, Joseph
Publicado em 2000

Neutralizing antibody and anti-retroviral drug sensitivities of HIV-1 isolates resistant to small molecule CCR5 inhibitors

Por Pugach, Pavel, Ketas, Thomas J., Michael, Elizabeth, Moore, John P.
Publicado em 2008

A Cell Line-Based Neutralization Assay for Primary Human Immunodeficiency Virus Type 1 Isolates That Use either the CCR5 or the CXCR4 Coreceptor

Por Trkola, Alexandra, Matthews, Jamie, Gordon, Cynthia, Ketas, Tom, Moore, John P.
Publicado em 1999

Genetic Subtypes, Humoral Immunity, and Human Immunodeficiency Virus Type 1 Vaccine Development

Por Moore, John P., Parren, Paul W. H. I., Burton, Dennis R.
Publicado em 2001

How Can HIV-Type-1-Env Immunogenicity Be Improved to Facilitate Antibody-Based Vaccine Development?

Por Klasse, Per Johan, Sanders, Rogier W., Cerutti, Andrea, Moore, John P.
Publicado em 2012

V3 determinants of HIV-1 escape from the CCR5 inhibitors Maraviroc and Vicriviroc

Por Berro, Reem, Klasse, Per Johan, Moore, John P., Sanders, Rogier W.
Publicado em 2012

Animal models for microbicide studies

Por Veazey, Ronald S., Shattock, Robin J, Klasse, Per Johan, Moore, John P.
Publicado em 2012